Related Experiment Video
Updated: Jun 20, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma:
Chad Tang1, Aaron Seo2, Alexander D Sherry3
1Department of Genitourinary Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Better tools are needed for clinical decision-making in oligometastatic clear-cell renal cell carcinoma (ccRCC). Plasma KIM-1 concentrations and circulating tumor DNA (ctDNA) were measured in a clinical trial evaluating metastasis-directed therapy (MDT) for oligometastatic ccRCC (NCT03575611). Shorter systemic therapy-free survival (STFS) was associated with high KIM-1 at baseline (hazard ratio per log10 pg/ml [HR]: 2.45, 95% confidence interval [CI] 1.48-4.08; p < 0.001), the end of radiation therapy (HR 2.56, 95% CI 1.56-4.21; p < 0.001), and 3-mo follow-up (HR 3.22, 95% CI 1.91-5.43; p < 0.001). KIM-1 was also associated with progression-free survival and overall survival. In multivariable analysis, both KIM-1 and ctDNA molecular residual disease status were independently associated with STFS when measured at baseline (KIM-1: HR 1.91, 95% CI 1.03-3.55; p = 0.041; ctDNA: HR 2.47, 95% CI 1.08-5.64; p = 0.03) and 3-mo follow-up (KIM-1: HR 2.22, 95% CI 1.09-4.51; p = 0.03; ctDNA: HR 2.70, 95%CI 1.09-6.67; p = 0.03). After elastic net-informed selection, Weibull regression fitted with four clinical variables plus baseline KIM-1 and ctDNA yielded a prognostic model (K-COMPASS) for STFS that demonstrated favorable discrimination (C index 0.76) and calibration. In conclusion, plasma KIM-1 and ctDNA were independently associated with patient outcomes across time points, and their prognostic value further improved with the addition of clinical variables.
Related Concept Videos
Cancers Originate from Somatic Mutations in a Single Cell
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Survival Analysis

